x

Posted 17 May, 2022

INOVIO PHARMACEUTICALS, INC. appointed new CEO

CEO Change detected for ticker Nasdaq:INO in a 8-K filed on 17 May, 2022.


  On May 16, 2022, following the conclusion of the 2022 Annual Meeting of Stockholders (the "Annual Meeting") of Inovio Pharmaceuticals, Inc. (the "Company"), the board of directors (the "Board") of the Company appointed Jacqueline E. Shea, Ph.D., the Company's President and Chief Executive Officer, to serve as a director of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of INOVIO PHARMACEUTICALS, INC.
Health Care/Life Sciences • Biotechnology
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Market Cap
$71.1M
View Company Details
INOVIO PHARMACEUTICALS, INC. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. 

On May 16, 2022, following the conclusion of the 2022 Annual Meeting of Stockholders (the "Annual Meeting") of Inovio Pharmaceuticals, Inc. (the "Company"), the board of directors (the "Board") of the Company appointed Jacqueline E. Shea, Ph.D., the Company's President and Chief Executive Officer, to serve as a director of the Company. Dr. Shea's term will continue until the Company's 2023 Annual Meeting of Stockholders. There is no arrangement or understanding between Dr. Shea and any other person pursuant to which she was selected as a director of the Company, and there is no family relationship between Dr. Shea and any of the Company's other directors or executive officers. The Company is not aware of any transaction involving Dr. Shea requiring disclosure under Item 404(a) of Regulation S-K. Biographical information about Dr. Shea is contained in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on March 25, 2022 (the "Proxy Statement") and is incorporated herein by reference.